专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2465935A3 Recombinant human interferon-like proteins 有权转让
标题翻译：重组人干扰素样蛋白
公开(公告)号：EP2465935A3
公开(公告)日：2012-08-15
申请号：EP12159128.3
申请日：2007-06-22
申请人： Novagen Holding Corporation
发明人： Wang, Haitao , Mao, Chunsheng , Li, Jizhi , Wang, Ling , Du, Yong , Liu, Longbin , Xu, Jing , Zhang, Rui
IPC分类号： C12N15/20 , A61K38/21 , A61P31/12 , A61P35/00 , A61P37/02 , C07K14/555 , C07K19/00
CPC分类号： C07K14/56 , A61K38/00 , C07K14/555
摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

2. 发明授权

EP2465935B1 Recombinant human interferon-like proteins 有权转让
标题翻译：重组人干扰素样蛋白
公开(公告)号：EP2465935B1
公开(公告)日：2016-05-18
申请号：EP12159128.3
申请日：2007-06-22
申请人： Novagen Holding Corporation
发明人： Wang, Haitao , Mao, Chunsheng , Li, Jizhi , Wang, Ling , Du, Yong , Liu, Longbin , Xu, Jing , Zhang, Rui
IPC分类号： C12N15/20 , A61K38/21 , A61P31/12 , A61P35/00 , A61P37/02 , C07K14/555 , C07K19/00
CPC分类号： C07K14/56 , A61K38/00 , C07K14/555
摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-±2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

3. 发明公开

EP2465935A2 Recombinant human interferon-like proteins 有权转让
标题翻译：重组蛋白质干扰素
公开(公告)号：EP2465935A2
公开(公告)日：2012-06-20
申请号：EP12159128.3
申请日：2007-06-22
申请人： Novagen Holding Corporation
发明人： Wang, Haitao , Mao, Chunsheng , Li, Jizhi , Wang, Ling , Du, Yong , Liu, Longbin , Xu, Jing , Zhang, Rui
IPC分类号： C12N15/20 , A61K38/21 , A61P31/12 , A61P35/00 , A61P37/02 , C07K14/555 , C07K19/00
CPC分类号： C07K14/56 , A61K38/00 , C07K14/555
摘要： This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.
摘要翻译：本申请涉及重组人类干扰素样蛋白。在一个实施方案中，描述了与天然存在的人干扰素α2b（HuIFN-±2b）相比，通过基因改组技术产生的重组蛋白具有增强的抗病毒和抗增殖活性。本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。优选地，多核苷酸选自各自具有与SEQ ID：No.1至少93％相同的序列的多核苷酸，并且所述蛋白质选自蛋白质组，其各自具有与SEQ ID NO：至少85％相同的氨基酸序列否：2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗（例如病毒性疾病和癌症）有反应的病症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式